🏛️ Verified NIH Record • Updated 2025-07-28
Higher vs. Lower Dose Heparin for PCI (NCT04049591)
🟢 Recruiting Observational / Diagnostic 💊 Investigational Drug / Biologic Sponsor: Population Health Research Institute
🩺 Plain-English Summary (8th-Grade Level)
HD PCI is a multicenter, randomized, registry-based, cluster crossover design trial of higher dose versus lower dose heparin in patients undergoing elective percutaneous coronary intervention (PCI).
Who can join: To join this study, participants generally need to meet the listed inclusion criteria (1 items) and avoid the listed exclusions (6 items).
Location: Hamilton Health Sciences, General Hospital — Hamilton, Ontario
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistCheck every box below. If you can check all of them, you may meet the study's basic screening requirements (final eligibility is confirmed by the site team).
Usually NOT eligible if any of the following apply:
- Exclusion Criteria:
- Age \<18 years
- Planned chronic total occlusion PCI
- Non-resident precluding follow up through local registries Hospital (Cluster) Eligibility Criteria Hospitals will be eligible to participate if they meet the following criteria:
- Submit PCI procedure data to a compatible registry that is able to provide data for the trial
- Site agrees to manage patients as per the higher or lower dose heparin policy in place during the given crossover period
🔍 Extracted verbatim from the official NIH eligibility criteria. Always confirm with the study coordinator.
📍 All Participating Trial Locations (1 Sites)
- Hamilton Health Sciences, General Hospital — Hamilton, Ontario
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.